Investigation the Effect of Montelukast in COVID-19
Status:
Not yet recruiting
Trial end date:
2021-05-30
Target enrollment:
Participant gender:
Summary
Small molecule inhibitors have previously been investigated in different studies as possible
therapeutics in the treatment of SARS-CoV-2. In the current drug repurposing study, the
investigators identified the leukotriene (D4) receptor antagonist Montelukast as a novel
agent that simultaneously targets two important drug targets of SARS-CoV-2. The investigators
initially demonstrated the dual inhibition (main protease and Spike/ACE2) profile of
Montelukast through multiscale molecular modeling studies. Next, the investigators
characterized its effect on both targets by different in vitro experiments including the
Fluorescent Resonance Energy Transfer (FRET)-based main protease enzyme inhibition assay,
surface plasmon resonance (SPR) spectroscopy, pseudovirus neutralization on HEK293T / hACE2,
and virus neutralization assay using xCELLigence MP real time cell analyzer.
Phase:
Phase 2
Details
Lead Sponsor:
Bahçeşehir University
Collaborators:
Medipol University The Scientific and Technological Research Council of Turkey